Published • loading... • Updated
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
- Elixiron Immunotherapeutics announced positive interim Phase 2 results for enrupatinib, a drug targeting neuroinflammation in Alzheimer's disease patients in a proof-of-concept study.
- The study showed that enrupatinib is safe, well tolerated, and effectively engages its target by reducing neuroinflammation as measured by TSPO-PET imaging in a biomarker-selected subgroup.
- No drug-related serious adverse events were reported among the seven assessed participants.
- In a subgroup of biomarker-defined patients, 80% showed significant reductions in neuroinflammation, with one participant exhibiting notable cognitive improvements, leading to plans for a placebo-controlled confirmatory study.
Insights by Ground AI
44 Articles
44 Articles
Bennington Banner+43 Reposted by 43 other sources
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
CAMBRIDGE, Mass. and TAIPEI, June 10, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced positive interim results from its ongoing Phase 2 proof-of-concept study of enrupatinib (EI-1071),…
Coverage Details
Total News Sources44
Leaning Left5Leaning Right3Center18Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 19%
C 69%
12%
Factuality
To view factuality data please Upgrade to Premium
